These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 2108855)
1. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Turpie AG; Levine MN; Hirsh J; Ginsberg JS; Cruickshank M; Jay R; Gent M Chest; 1990 Apr; 97(4 Suppl):172S-175S. PubMed ID: 2108855 [TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Goldhaber SZ; Meyerovitz MF; Green D; Vogelzang RL; Citrin P; Heit J; Sobel M; Wheeler HB; Plante D; Kim H Am J Med; 1990 Mar; 88(3):235-40. PubMed ID: 2106783 [TBL] [Abstract][Full Text] [Related]
3. Studies on the medical treatment of deep vein thrombosis. Schulman S Acta Med Scand Suppl; 1985; 704():1-68. PubMed ID: 3913282 [TBL] [Abstract][Full Text] [Related]
4. Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study. Schweizer J; Elix H; Altmann E; Hellner G; Forkmann L Vasa; 1998 Aug; 27(3):167-71. PubMed ID: 9747153 [TBL] [Abstract][Full Text] [Related]
5. Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis. Verhaeghe R; Besse P; Bounameaux H; Marbet GA Thromb Res; 1989 Jul; 55(1):5-11. PubMed ID: 2506661 [TBL] [Abstract][Full Text] [Related]
6. [Thrombolytic therapy of deep venous thrombosis with rt-PA]. Zimmermann R; Horn A; Harenberg J; Diehm C; Müller-Bühl U; Kübler W Klin Wochenschr; 1988; 66 Suppl 12():137-42. PubMed ID: 3126342 [TBL] [Abstract][Full Text] [Related]
7. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384 [TBL] [Abstract][Full Text] [Related]
8. Double-blind, randomized comparison of systemic continuous infusion of 0.25 versus 0.50 mg/kg/24 h of alteplase over 3 to 7 days for treatment of deep venous thrombosis in heparinized patients: results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) trial. Bounameaux H; Banga JD; Bluhmki E; Coccheri S; Fiessinger JN; Haarmann W; Lockner D; Mahler F; Ninet J; Schneider PA Thromb Haemost; 1992 Mar; 67(3):306-9. PubMed ID: 1641820 [TBL] [Abstract][Full Text] [Related]
9. Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. Marder VJ; Brenner B; Totterman S; Francis CW; Rubin R; Rao AK; Kessler CM; Kwaan HC; Sharma GV; Fong KL J Lab Clin Med; 1992 May; 119(5):485-95. PubMed ID: 1583404 [TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator. Zimmerman R; Gürsoy A; Horn A; Harenberg J; Diehm C; Kübler W Semin Thromb Hemost; 1991 Jan; 17(1):48-54. PubMed ID: 1904629 [TBL] [Abstract][Full Text] [Related]
12. Short-term response to thrombolytic therapy in deep venous thrombosis: predictive value of venographic appearance. Meyerovitz MF; Polak JF; Goldhaber SZ Radiology; 1992 Aug; 184(2):345-8. PubMed ID: 1620826 [TBL] [Abstract][Full Text] [Related]
13. Tissue plasminogen activator for the treatment of deep venous thrombosis of the lower extremity: a systematic review. Forster A; Wells P Chest; 2001 Feb; 119(2):572-9. PubMed ID: 11171740 [TBL] [Abstract][Full Text] [Related]
14. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Collen D; Stassen JM; De Cock F Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288 [TBL] [Abstract][Full Text] [Related]
15. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits. Agnelli G; Pascucci C; Cosmi B; Nenci GG Blood; 1990 Nov; 76(10):2030-6. PubMed ID: 2122919 [TBL] [Abstract][Full Text] [Related]
16. [The treatment of deep venous thrombosis. Thrombolysis vs heparin]. Schmutzler R Phlebologie; 1990; 43(4):656-65; discussion 666. PubMed ID: 2093922 [TBL] [Abstract][Full Text] [Related]
17. [Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct]. Bleifeld W; Verstraete M; Brower RW; Collen D; Dunning AJ; Lubsen J; Michel PL; Schofer J; Vanhaecke J; Van de Werf F Klin Wochenschr; 1988; 66 Suppl 12():86-92. PubMed ID: 3126349 [TBL] [Abstract][Full Text] [Related]
18. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
19. Thrombolysis in venous thromboembolism. An international perspective. Goldhaber SZ Chest; 1990 Apr; 97(4 Suppl):176S-181S. PubMed ID: 2108856 [TBL] [Abstract][Full Text] [Related]
20. [rt-PA in extracardiac thromboembolic vascular occlusions]. Cortellaro M; Cofrancesco E; Polli EE Ann Ital Med Int; 1990; 5(1):61-9. PubMed ID: 2119673 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]